ERBB2 and congestive heart failure: In addition, HER2 is expressed in many normal tissues, giving systemic HER2-targeted antibody therapy the potential to cause toxicity in a subset of patients, including cardiac myopathy, congestive heart failure, and pulmonary toxicity [14], [15].